TickerFacts.

Dyadic International Inc (DYAI): Cost of Revenue

Annual figures by period end, from SEC filings.

$2.32M
Year ended 2025-12-31
$3.18M
Trailing 12 months to 2026-06-30
+3.0%
3-year compound annual growth
+10.2%
5-year compound annual growth
2017-12-31: $680.2K2018-12-31: $1.03M2019-12-31: $1.46M2020-12-31: $1.42M2021-12-31: $1.94M2022-12-31: $2.12M2023-12-31: $1.98M2024-12-31: $1.19M2025-12-31: $2.32M$2.32M
2017-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$2.32M+94.2%2026-03-25, From 2025-01-01
2024-12-31$1.19M-39.5%2026-03-25, From 2024-01-01
2023-12-31$1.98M-6.9%2025-03-26, From 2023-01-01
2022-12-31$2.12M+9.2%2024-03-28, From 2022-01-01
2021-12-31$1.94M+36.5%2023-03-29, From 2021-01-01
2020-12-31$1.42M-2.4%2022-03-29, From 2020-01-01
2019-12-31$1.46M+42.1%2021-03-30, From 2019-01-01
2018-12-31$1.03M+51.0%2020-03-30, From 2018-01-01
2017-12-31$680.2Kn/a2019-03-27, From 2017-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Dyadic International Inc (DYAI)2025-12-31$2.32M+94.2%
Humacyte, Inc. (HUMA)2025-12-31$9.70Mn/a
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$931.0K+10.3%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$1.36Mn/a
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$3.96M+220.1%
Pluri Inc. (PLUR)2026-06-30$563.0K-17.4%
Alpha Cognition Inc. (ACOG)2025-12-31$603.4Kn/a
Lineage Cell Therapeutics, Inc. (LCTX)2024-12-31$334.0K-50.2%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$3.99Mn/a

Compare DYAI, HUMA, ZEOX, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗